PIK3CA and neoplasm: In a clinical study of therapies for solid tumors with PIK3CA mutations, in which co-occurring mutations such as the FBXW7 mutation were also detected, the investigators uniquely found that Alpelisib (BYL719) selectively inhibited PI3Kα in solid tumors with PIK3CA mutations containing the FBXW7 co-occurring mutation, effectively inhibiting tumor growth and improving patient survival [269].